Akdeniz, F.T.Avsar, O.2025-04-162025-04-1620252732-778710.21873/cdp.104332-s2.0-86000055584https://doi.org/10.21873/cdp.10433https://hdl.handle.net/20.500.14517/7828Background/Aim: Lung cancers are malignant neoplasms located in the lung tissues. miRNAs are short non-coding RNAs. It is known that miRNA-124 prevents metastasis in lung cancers. The phosphatidylinositol 3-kinases (PI3K) signaling pathway, a basic signaling pathway interconnected with other pathways, is activated during cancer development. This study aimed to compare miRNA-124-5p and PI3K serum levels in patient and control groups. Materials and Methods: miRNA isolated from patient and control serum samples were converted into cDNA. miRNA- 124-5p expression was determined using Real-Time PCR and a SYBR GREEN kit. PI3K serum level was determined using the Enzyme-Linked Immunosorbent Assay. Results: While miRNA-124-5p serum level was statistically significantly lower in the patient group (p>0.02), serum PI3K level was higher in the patient group than in the control group but the difference was not statistically significant (p>0.11). Conclusion: Lower serum levels of miRNA-124-5p and high PI3K levels observed in the patient group, compared to the control group, may be associated with a poor disease prognosis. © 2025 The Author(s). Anticancer Research is published by the International Institute of Anticancer Research.eninfo:eu-repo/semantics/openAccessLung CancerMirna124Pi3KReal Time PcrArticleN/AN/A52223229